The Tal1 Oncoprotein Inhibits E47-mediated Transcription

• DOI: 10.1074/jbc.273.12.7030
• Publication Date: 2002-07-26T15:04:43Z
• Authors: Steven T. Park; Xiao-Hong Sun
• Keywords: Cyclin-Dependent Kinase Inhibitor p21; 0301 basic medicine; Transcription, Genetic; Recombinant Fusion Proteins; Transcription Factor 7-Like 1 Protein; DNA; Cell Line; DNA-Binding Proteins; 03 medical and health sciences; Cyclins; Proto-Oncogene Proteins; Basic Helix-Loop-Helix Transcription Factors; Humans; TCF Transcription Factors; Dimerization; T-Cell Acute Lymphocytic Leukemia Protein 1; HeLa Cells; Protein Binding; Transcription Factors

The Tal1 oncogene is a class II basic helix-loop-helix (bHLH) transcription factor, overexpressed in as much as 60% of T cell acute lymphoblastic leukemia cases. Like other class II bHLH proteins, Tal1 can heterodimerize with the class I bHLH proteins, such as E47, and bind to a DNA recognition sequence termed E box. Therefore, it is believed that the oncogenic capacity of Tal1 lies in its ability, as a heterodimer with E47, to activate aberrantly a set of "leukemogenic" genes in T cells. However, compared with E47 homodimers, Tal1/E47 heterodimers are very poor transactivators. Thus the effect of Tal1 is actually to inhibit E47 homodimer activity. Here we propose that the transforming properties of Tal1 are the result of its ability to inhibit E47 activity. We address the mechanism of Tal1 inhibition and demonstrate that Tal1/E47 heterodimers cannot activate transcription because their respective activation domains are incompatible. Furthermore, we present data showing that Tal1 can inhibit E47-mediated activation of the CIP1 gene. Finally, we demonstrate that Tal1 inhibits E47 activity in leukemic T cells.